Gammora

Phase 2Small molecule

FFederal University of São Paulo

Gammora is one of 5 small molecule programs targeting Antiretroviral Treatment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Antiretroviral TreatmentRecruiting

Antiretroviral TreatmentPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Antiretroviral Treatment

#DrugCompanyPhaseTrials

Tivicay

GSK

Phase 3

3 2

Olumiant

Eli Lilly

Phase 2

1 3

Rapamune

PPrism Pharmaceuticals

Phase 2

1 4

DOR/ISL

Merck & Co.

Phase 3

1 5

Gammora

FFederal University of São Paulo

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Antiretroviral Treatment1 trial

Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV

Recruiting·FFederal University of São Paulo·Phase 2·NCT06799650·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gammora. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gammora compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gammora. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Federal University of São Paulo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFederal University of São Paulo

Gammora

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Antiretroviral Treatment1 trial

References

Drug Info

Quick Facts

Related News